Anti-depressant medication use and C-reactive protein: Results from two population-based studies

Brain, Behavior, and Immunity

Volumn 25, Issue 1, 2011, Pages 168-173

  Hamer, Mark ^a   Batty, G D ^a,b,c   Marmot, Michael G ^a   Singh Manoux, Archana ^a,d   Kivimäki, Mika ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

Author keywords

Cardiovascular risk; Depression; Inflammation; Selective serotonin reuptake inhibitors; Tricyclic antidepressant

Indexed keywords

ANTIDEPRESSANT AGENT; C REACTIVE PROTEIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DEPRESSION; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; COHORT STUDIES; DEPRESSIVE DISORDER; DRUG UTILIZATION; FEMALE; HEALTH SURVEYS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POPULATION; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; SCOTLAND; SEROTONIN UPTAKE INHIBITORS;

EID: 78649330191     PISSN: 08891591     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbi.2010.09.013     Document Type: Article

References (36)

1. Aronne L.J., Segal K.R. Weight gain in the treatment of mood disorders. J. Clin. Psychiatry 2003, 64(Suppl. 8):22-29.
2. Andersohn F., Schade R., Suissa S., Garbe E. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am. J. Psychiatry 2009, 166:591-598.
3. Bisoendial R.J., Kastelein J.J., Levels J.H., Zwaginga J.J., van den Bogaard B., Reitsma P.H., Meijers J.C., Hartman D., Levi M., Stroes E.S. Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ. Res. 2005, 96:714-716.
4. Chen Y., Guo J.J., Li H., Wulsin L., Patel N.C. Risk of cerebrovascular events associated with antidepressant use in patients with depression: a population-based, nested case-control study. Ann. Pharmacother. 2008, 42:177-184.
5. Cohen H.W., Gibson G., Alderman M.H. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am. J. Med. 2000, 108:2-8.
6. Danesh J., Wheeler J.D., Hirschfield G.M. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 2004, 350:1387-1397.
7. Dawood T., Lambert E.A., Barton D.A., Laude D., Elghozi J.L., Esler M.D., Haikerwal D., Kaye D.M., Hotchkin E.J., Lambert G.W. Specific serotonin reuptake inhibition in major depressive disorder adversely affects novel markers of cardiac risk. Hypertens. Res. 2007, 30:285-293.
8. Dinan T.G. Inflammatory markers in depression. Curr. Opin. Psychiatry 2009, 22:32-36.
9. Elliott P., Chambers J.C., Zhang W., Clarke R., Hopewell J.C., Peden J.F., Erdmann J., Braund P., Engert J.C., Bennett D., Coin L., Ashby D., Tzoulaki I., Brown I.J., Mt-Isa S., McCarthy M.I., Peltonen L., Freimer N.B., Farrall M., Ruokonen A., Hamsten A., Lim N., Froguel P., Waterworth D.M., Vollenweider P., Waeber G., Jarvelin M.R., Mooser V., Scott J., Hall A.S., Schunkert H., Anand S.S., Collins R., Samani N.J., Watkins H., Kooner J.S. Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 2009, 302:37-48.
10. Fosbøl E.L., Gislason G.H., Poulsen H.E., Hansen M.L., Folke F., Schramm T.K., Olesen J.B., Bretler D.M., Abildstrøm S.Z., Sørensen R., Hvelplund A., Køber L., Torp-Pedersen C. Prognosis in heart failure and the value of {beta}-blockers are altered by the use of antidepressants and depend on the type of antidepressants used. Circ. Heart Fail. 2009, 2:582-590.
11. Goldberg D.P., Gater R., Sartorius N., Ustun T.B., Piccinelli M., Gureje O., Rutter C. The validity of two versions of the GHQ in the WHO study of mental illness in general health care. Psychol. Med. 1997, 27:191-197.
12. Hamer M., Molloy G.J., de Oliveira C., Demakakos P. Persistent depressive symptomatology and inflammation: do health behaviours and weight control mediate this relationship?. Brain Behav. Immun. 2009, 23:413-418.
13. Kemp A.H., Quintana D.S., Gray M.A., Felmingham K.L., Brown K., Gatt J. Impact of depression and antidepressant treatment on heart rate variability: a review and meta-analysis. Biol. Psychiatry 2010, 67:1067-1074.
14. Kivimäki M., Lawlor D.A., Davey Smith G., Kumari M., Britton A., Casas J.P., Shah T., Brunner E., Timpson N.J., Halcox J.P., Miller M.A., Humphries S.E., Deanfield J., Marmot M.G., Hingorani A. Does high C-reactive protein concentration increase atherosclerosis? The Whitehall II study. PLoS ONE 2008, 3:e3013.
15. Kivimäki M., Tabak A.G., Lawlor D.A., Batty G.D., Singh-Manoux A., Jokela M., Virtanen M., Salo P., Oksanen T., Pentti J., Witte D.R., Vahtera J. Antidepressant use before and after the diagnosis of type 2 diabetes: a longitudinal modeling study. Diabetes Care 2010, 33:1471-1476.
16. Knol M.J., Geerlings M.I., Egberts A.C., Gorter K.J., Grobbee D.E., Heerdink E.R. No increased incidence of diabetes in antidepressant users. Int. Clin. Psychopharmacol. 2007, 22:382-386.
17. Krantz D.S., Whittaker K.S., Francis J.L., Rutledge T., Johnson B.D., Barrow G., McClure C., Sheps D.S., York K., Cornell C., Bittner V., Vaccarino V., Eteiba W., Parashar S., Vido D.A., Merz C.N. Psychotropic medication use and risk of adverse cardiovascular events in women with suspected coronary artery disease: outcomes from the Women's Ischemia Syndrome Evaluation (WISE) study. Heart 2009, 95:1901-1906.
18. Licht C.M., de Geus E.J., Seldenrijk A., van Hout H.P., Zitman F.G., van Dyck R., Penninx B.W. Depression is associated with decreased blood pressure, but antidepressant use increases the risk for hypertension. Hypertension 2009, 53:631-638.
19. O'Brien S.M., Scott L.V., Dinan T.G. Antidepressant therapy and C-reactive protein levels. Br. J. Psychiatry 2006, 188:449-452.
20. O'Connor C.M., Jiang W., Kuchibhatla M., Mehta R.H., Clary G.L., Cuffe M.S., Christopher E.J., Alexander J.D., Califf R.M., Krishnan R.R. Antidepressant use, depression, and survival in patients with heart failure. Arch. Intern. Med. 2008, 168:2232-2237.
21. Olfson M., Marcus S.C. National patterns in antidepressant medication treatment. Arch. Gen. Psychiatry 2009, 66:848-856.
22. Pizzi C., Mancini S., Angeloni L., Fontana F., Manzoli L., Costa G.M. Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clin. Pharmacol. Ther. 2009, 86:527-532.
23. Pariante C.M. Risk factors for development of depression and psychosis. Glucocorticoid receptors and pituitary implications for treatment with antidepressant and glucocorticoids. Ann. N. Y. Acad. Sci. 2009, 1179:144-152.
24. Pace T.W., Miller A.H. Cytokines and glucocorticoid receptor signaling. Relevance to major depression. Ann. N. Y. Acad. Sci. 2009, 1179:86-105.
25. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon R.O., Criqui M., Fadl Y.Y., Fortmann S.P., Hong Y., Myers G.L., Rifai N., Smith S.C., Taubert K., Tracy R.P., Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499-511. Centers for Disease Control and Prevention; American Heart Association.
26. Reid S., Barbui C. Long term treatment of depression with selective serotonin reuptake inhibitors and newer antidepressants. BMJ 2010, 340:c1468.
27. Roose S.P., Laghrissi-Thode F., Kennedy J.S., Nelson J.C., Bigger J.T., Pollock B.G., Gaffney A., Narayan M., Finkel M.S., McCafferty J., Gergel I. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998, 279:287-291.
28. Rubin R.R., Ma Y., Marrero D.G., Peyrot M., Barrett-Connor E.L., Kahn S.E., Haffner S.M., Price D.W., Knowler W.C. Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program. Diabetes Care 2008, 31:420-426.
29. Smoller J.W., Allison M., Cochrane B.B., Curb J.D., Perlis R.H., Robinson J.G., Rosal M.C., Wenger N.K., Wassertheil-Smoller S. Antidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women in the Women's Health Initiative study. Arch. Intern. Med. 2009, 169:2128-2139.
30. Scottish Health Survey Publications. (accessed November 2007). http://www.scotland.gov.uk/Topics/Statistics/Browse/Health/scottish-health-survey/Publications.
31. Tata L.J., West J., Smith C., Farrington P., Card T., Smeeth L., Hubbard R. General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction. Heart 2005, 91:465-471.
32. Taylor C.B., Youngblood M.E., Catellier D., Veith R.C., Carney R.M., Burg M.M., Kaufmann P.G., Shuster J., Mellman T., Blumenthal J.A., Krishnan R., Jaffe A.S., ENRICHD Investigators Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch. Gen. Psychiatry 2005, 62:792-798.
33. Tousoulis D., Drolias A., Antoniades C., Vasiliadou C., Marinou K., Latsios G., Stefanadi E., Gounari P., Siasos G., Papageorgiou N., Trikas A., Stefanadis C. Antidepressive treatment as a modulator of inflammatory process in patients with heart failure: effects on proinflammatory cytokines and acute phase protein levels. Int. J. Cardiol. 2009, 134:238-243.
34. Verma S., Wang C.H., Li S.H., Dumont A.S., Fedak P.W., Badiwala M.V., Dhillon B., Weisel R.D., Li R.K., Mickle D.A., Stewart D.J. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002, 106:913-919.
35. Venugopal S.K., Devaraj S., Yuhanna I., Shaul P., Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002, 106:1439-1441.
36. Zacho J., Tybjaerg-Hansen A., Jensen J.S., Grande P., Sillesen H., Nordestgaard B.G. Genetically elevated C-reactive protein and ischemic vascular disease. N. Engl. J. Med. 2008, 359:1897-1908.